CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2013-10-23): Gilead's hepatitis C drug sofosbuvir safe, effective: FDA reviewers

Regulatory

Gilead's hepatitis C drug sofosbuvir safe, effective: FDA reviewers

Last Updated: 2013-10-23 12:32:09 -0400 (Reuters Health)

(Reuters) - Sofosbuvir from Gilead Sciences is safe and effective when used in combination with other therapies to treat hepatitis C, according to reviewers with the U.S. Food and Drug Administration.

Their review was posted on the FDA website on Wednesday ahead of an October 25 meeting of an outside panel of medical experts who will recommend whether or not the agency should approve the drug.

"The currently available data support a favorable benefit-risk assessment for the use of sofosbuvir as part of a combination regimen for the treatment of chronic hepatitis C," the reviewers said.

"No major safety issues associated with sofosbuvir use have been identified to date."

Gilead is seeking approval to market the drug in combination with ribavirin for patients with HCV genotype 2 and genotype 3, and for patients awaiting a liver transplant.

If approved, this would be the first all-oral treatment for genotypes 2 and 3. Current therapies typically include oral ribavirin and the once-weekly injectable drug interferon. Both can cause debilitating side effects.

Gilead is also seeking to market sofosbuvir in combination with ribavirin and interferon for patients with genotype 1, regardless of prior treatments, and for patients with genotypes 4, 5 and 6 who have not previously been treated.

Chronic hepatitis C affects at least 3 million people in the United States, according to the U.S. Centers for Disease Control. HCV genotype 1 is the most common form, accounting for about 70% of cases.

Current standard treatments for genotype 1 often include an oral protease inhibitor, such as boceprevir (Victrelis, Merck) and telaprevir (Incivek, Vertex).

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.